Sort   by:  
 Page size 
MetabolomicsPRDM15 is a master regulator of metabolism essential to sustain B-cell lymphomagenesis
PRDM family members are sequence-specific transcriptional regulators involved in cell identity and fate determination and are often dysregulated in cancer. The PRDM15 gene is of particular interest, given its relatively low expression in adult tissues and its overexpression in follicular lymphomas (...
2025-06-16 | MTBLS1639 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14634 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma (Glucose Tracer)
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14641 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma (CAR-T Metabolites)
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14640 | MetaboLights
MetabolomicsA polyamine-centric blood-based metabolite panel predictive of poor response to CAR T-cell therapy in large B cell lymphoma

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (r/r) large B-cell lymphoma (LBCL) results in durable response in only a subset of patients. MYC overexpression in LBCL tumors is associated with poor response to treatment. We tested whether a MYC-driven polyamin...

2022-10-31 | MTBLS5381 | MetaboLights
MetabolomicsAggressive breast cancers secrete heme metabolites to alter macrophage immune suppression and function
The heme catabolism pathway is often elevated in aggressive cancers; however, the impact of this pathway and some of its byproducts on the tumor microenvironment remain largely unknown. In human breast cancers, tumor expression of the heme catabolizing enzyme heme oxygenase-1 (HO-1/HMOX1) is positiv...
2026-04-24 | MTBLS14278 | MetaboLights
MetabolomicsGut Microbiota-Mediated Tryptophan Metabolism Plays Dual Effects in Diffuse Large B-Cell Lymphoma via Regulating 3-IAA/5-HTP Balance and Antitumor Immunity
Timing-dependent tryptophan diets differentially modulate DLBCL outcomes via microbiota-derived 3-IAA (pre-inoculation, anti-tumor) versus 5-HTP (post-inoculation, pro-tumor), with pectin restoring microbial balance to enable a timed tryptophan-pectin precision nutrition strategy for enhanced immuno...
2026-09-07 | MTBLS15570 | MetaboLights
ProteomicsIntegrated cellular and plasma proteomics reveals common and systemic signatures in contrasting B-cell cancers
Approximately 800,000 leukaemia and lymphoma cases are diagnosed worldwide each year. Burkitt’s lymphoma and chronic lymphocytic leukaemia represent contrasting examples of B-cell cancers, modelled by Eμ-myc and Eμ-TCL1 mice, respectively. To better understand B-cell cancers and systemic effects of ...
ORGANISM(S): Mus musculus (Mouse) 
2017-01-10 | PXD004608 | Pride
Eµ-myc Lymphoma B-cell Oncogenesis Proteomics Eµ-tcl1 Plasma Leukaemia 
TranscriptomicsATM-deficient B cell lymphomas
Ataxia-telangiectasia mutated (ATM) kinase plays a central role in maintaining genomic integrity. In both humans and mice, ATM deficiency is associated with an increased incidence of lymphoid cancers that are primarily T cell in origin. We demonstrate here that when T cells are removed as targets fo...
ORGANISM(S): Mus musculus 
2015-12-09 | E-GEOD-68505 | biostudies-arrayexpress
ProteomicsABPP of Ibrutinib Resistance in B Cell Malignancies
Ibrutinib,a novel Bruton'styrosine kinase inhibitor, demonstrated high response rates in B-cell lymphomas but a growing number of ibrutinib treated patients relapse with resistance, fulminant progression and accelerated mortality. Using chemical proteomics and a high-throughput ex vivo assay in a re...
ORGANISM(S): Homo sapiens (Human) 
2018-10-26 | PXD005734 | Pride
Ibrutinib Activity-based protein profiling B-cell cancers Lc-ms/ms 
Sort   by:  
 Page size